RNA News Alert Prosensa Holding B.V. (RNA) 18.76 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Prosensa Holding B.V. (RNA) 18.76 $RNA

PTC Therapeutics Starts Rolling NDA Filing for Translarna - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:10PM CST
PTC Therapeutics (PTCT) initiated the process of a rolling submission of a new drug application to the FDA for Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy.
RNA: 18.76 (+0.10), SRPT: 13.88 (+0.47), PTCT: 51.66 (+0.76), BIOD: 1.36 (-0.04)

BioMarin and Prosensa Announce Expiration of the Hart-Scott-Rodino Waiting Period for BioMarin's Proposed Acquisition of Prosensa
GlobeNewswire - Wed Dec 24, 12:15PM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) and Prosensa Holding N.V. (Nasdaq:RNA) today announced the expiration of the mandatory waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act" , which occurred at 11:59 p.m. on December 23, 2014, with respect to BioMarin's pending acquisition of Prosensa.
BMRN: 88.18 (+0.89), RNA: 18.76 (+0.10)

BioMarin CEO Sees Big Future For Prosensa Drug
at Investor's Business Daily - Tue Dec 23, 3:11PM CST
BioMarin Pharmaceuticals raised a few eyebrows last month when it announced its latest buyout. BioMarin (BMRN) agreed to pay $680 million upfront for Prosensa Holding (RNA), a Dutch biotech developing a drug for Duchenne muscular dystrophy called...
BMRN: 88.18 (+0.89), RNA: 18.76 (+0.10), PTCT: 51.66 (+0.76), GSK: 42.85 (+0.11)

PTC Therapeutics begins rolling NDA for DMD
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 9:20AM CST

ROSG: 2.35 (+0.03), RNA: 18.76 (+0.10), SRPT: 13.88 (+0.47), PFE: 31.42 (-0.03), PTCT: 51.66 (+0.76)

Pfizer's Duchenne Muscular Dystrophy Drug in Phase II - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 6:07PM CST
Pfizer (PFE) has moved its experimental Duchenne muscular dystrophy treatment into a phase II study.
RNA: 18.76 (+0.10), SRPT: 13.88 (+0.47), PFE: 31.42 (-0.03), MYL: 56.97 (+0.39)

Pfizer commences Phase 2 study in Duchenne Muscular Dystrophy
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 9:10AM CST

ROSG: 2.35 (+0.03), RNA: 18.76 (+0.10), SRPT: 13.88 (+0.47), PFE: 31.42 (-0.03), PTCT: 51.66 (+0.76)

Twitter's Favorite Biotech and Pharma Stocks
Brian Orelli, The Motley Fool - Motley Fool - Tue Dec 16, 8:21AM CST
Mark Schoenebaum, the biotech and pharmaceutical analyst at Evercore ISI, asked the Twittersphere for their favorite drug stocks going into next year. What's your favorite stock for 2015 in biotech or Pharma? — Mark Schoenebaum...
BLUE: 88.76 (+3.23), BMRN: 88.18 (+0.89), TGTX: 16.03 (+0.33), BMY: 59.15 (-0.01), MACK: 10.91 (+0.36), FMI: 23.99 (-0.10), RNA: 18.76 (+0.10), GWPH: 68.08 (+1.82), SRPT: 13.88 (+0.47), MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36), ICPT: 151.49 (+5.85), THLD: 2.93 (+0.01), CEMP: 20.66 (+0.78), NVS: 93.91 (+0.66)

3 Traits of the Best Healthcare Stocks in 2014
Sean Williams, The Motley Fool - Motley Fool - Mon Dec 15, 6:20AM CST
Source: MercK & Co., Just when it looked as though the stock market couldn't possibly finish the year higher, after its swoon in October, it proved the naysayers wrong. As of this writing, the S&P 500 has risen by 11% for the year, a tad...
AVNR: 16.91 (+0.01), RNA: 18.76 (+0.10), ACHN: 13.06 (+1.22), EXAS: 27.60 (+0.39), AGIO: 109.67 (+2.45)

PROSENSA HOLDING N.V. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
PR Newswire - Fri Dec 12, 11:40AM CST
Rigrodsky & Long, P.A.:
BMRN: 88.18 (+0.89), RNA: 18.76 (+0.10)

Prosensa Holding (RNA) Upgraded From Sell to Hold
at The Street - Fri Dec 12, 6:10AM CST
Prosensa Holding (RNA) has been upgraded by TheStreet Ratings from Sell to Hold with a ratings score of C-.
RNA: 18.76 (+0.10)

The Nominees for Best Biotechnology Co. CEO of 2014 Are...
at The Street - Fri Dec 12, 5:05AM CST
The CEOs of Exact Sciences, Idenix Pharma, Prosensa, Agios, Bluebird Bio and InterMune vie for the coveted title of Best Biotech CEO
BLUE: 88.76 (+3.23), RNA: 18.76 (+0.10), EXAS: 27.60 (+0.39), AGIO: 109.67 (+2.45)

Prosensa Wins Scrip 'Biotech Company of the Year' 2014 Award
GlobeNewswire - Mon Dec 08, 7:17AM CST
Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with a high unmet medical need, is delighted to have won the Scrip 'Biotech Company of the Year' Award for 2014, announced last week in London, UK.
RNA: 18.76 (+0.10)

Biotech Stock Mailbag: Aethlon Medical, Oxigene, Sarepta
at The Street - Fri Dec 05, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care.
OXGN: 1.59 (unch), BMRN: 88.18 (+0.89), RNA: 18.76 (+0.10), SRPT: 13.88 (+0.47)

RNA SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Prosensa Holding N.V. in Connection With the Fairness of the Sale of the Company to BioMarin Pharmaceutical Inc.
Business Wire - Thu Dec 04, 11:11AM CST
Levi & Korsinsky is investigating the Board of Directors of Prosensa Holding N.V. ("Prosensa" or "the Company" (Nasdaq:RNA) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to BioMarin Pharmaceutical Inc.
BMRN: 88.18 (+0.89), RNA: 18.76 (+0.10)

RNA INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation of the Board of Directors of Prosensa Holding N.V. in Connection With the Fairness of the Sale of the Company to BioMarin Pharmaceutical Inc. -- RNA
PR Newswire - Thu Dec 04, 11:05AM CST
Levi & Korsinsky is investigating the Board of Directors of Prosensa Holding N.V. ("Prosensa" or "the Company" (Nasdaq: RNA) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to BioMarin Pharmaceutical Inc.
BMRN: 88.18 (+0.89), RNA: 18.76 (+0.10)

Prosensa Holding N.V. Acquisition By BioMarin Pharmaceutical Inc. May Not Be In The Best Interests of RNA Shareholders
PR Newswire - Wed Dec 03, 3:11PM CST
The fairness of the proposed acquisition of Prosensa Holding N.V. ("RNA" or the "Company" by BioMarin Pharmaceutical Inc. ("BioMarin" is the subject of an examination by WeissLaw LLP, a national class action, shareholder rights law firm. The examination is focusing on possible breaches of fiduciary duty and other violations of law by the Board of Directors of RNA for agreeing to sell the Company to BioMarin. On November 24, 2014, the Company announced it had reached a definitive agreement for BioMarin to acquire RNA in a transaction valued at approximately $680 million. Under the terms of the agreement, RNA shareholders will receive $17.75 in cash for each RNA share they own.
BMRN: 88.18 (+0.89), RNA: 18.76 (+0.10)

Merger Opportunity: BioMarin To Adquire Prosensa
Maudes Capital - at Seeking Alpha - Wed Dec 03, 6:57AM CST

BMRN: 88.18 (+0.89), RNA: 18.76 (+0.10), GSK: 42.85 (+0.11)

Jim Cramer's Five Best Stock Picks for the Biotech Sector
at The Street - Tue Dec 02, 10:11AM CST
TheStreet's Jim Cramer has selected 12 sectors where he thinks investors should put their money. Biotech stocks have had a "monstrous" year. Here are Cramer's best picks.
BIIB: 340.89 (+5.13), BMRN: 88.18 (+0.89), RNA: 18.76 (+0.10), ISIS: 59.49 (+1.88), AGIO: 109.67 (+2.45), GSK: 42.85 (+0.11), SNY: 46.35 (+0.50), REGN: 400.12 (+6.07), CELG: 109.60 (+3.48)

SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Prosensa Holding N.V. And Encourages Investors To Contact The Firm For Additional Information
Business Wire - Mon Dec 01, 3:32PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Prosensa Holding N.V. ("Prosensa" or the "Company" (Nasdaq: RNA) relating to the proposed buyout of the Company by BioMarin Pharmaceuticals, Inc. ("BioMarin" .
RNA: 18.76 (+0.10)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Teva’s R&D Exit Puts Disclosure Questions in Focus

Updated Category News Views 92

An abrupt departure in the drug business is never just an HR memo. Teva Pharmaceutical Industries shares reportedly dropped about 8.74% after Eric Hughes, the company’s executive vice president of Global R&D and chief medical officer, left effective immediately. That kind of move rattles investors because R&D leadership is not decorative furniture at a pharmaceutical...

Continue Reading
ECW Puts $52 Million Behind Learning Through Crisis

Updated Category News Views 66

A reserve fund for a classroom is not glamorous, but it may be the smartest detail in this whole $52 million commitment. Education Cannot Wait has announced support for more than 300,000 children in Lebanon, Myanmar and South Sudan, where war, flooding and displacement have ripped ordinary schooling apart. The money is meant to restore learning, provide catch-up classes...

Continue Reading
Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire

Updated Category News Views 48

A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...

Continue Reading
Why Insurance Must Change as Family Assets Keep Growing

Updated Category News Views 73

A policy bought in the starter-home years can turn stale quietly while everything around it gets bigger, pricier and more complicated. That is the uncomfortable little truth behind Daniel C. DiCocco's discussion in HelloNation: families often treat insurance as a box checked long ago, even as they add property, savings, debt, children and fresh responsibilities. Static...

Continue Reading
Tigerlily Brings HIV Information to Women’s Health

Updated Category News Views 37

A stubborn information gap is exactly where Tigerlily Foundation is planting its flag. The nonprofit’s new national HIV education and awareness campaign, THE POWER OF U, expands work that began in breast cancer advocacy into another area where women need clear facts, trusted voices, and room to speak without being shamed for needing answers. This is not a story that...

Continue Reading
Rosalind Franklin University’s $23.8M Scholarship Win

Updated Category News Views 80

Twenty-three million dollars can disappear fast in graduate health education, which is exactly why Rosalind Franklin University’s campaign result deserves more than a polite round of applause. The university’s five-year Empowering Scholars effort closed in June 2026 with $23,836,272 raised, clearing its $20 million target by roughly 19%. In a world where institutions...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 58

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 79

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
Epilepsy Campaign Puts Patient Voices Before Investors

Updated Category News Views 46

An epilepsy diagnosis can turn ordinary family routines into a maze overnight, which is why awareness work deserves more than the usual polite nod and a colored ribbon. Mediaplanet's national Epilepsy Awareness campaign, launched November 20, 2026, brings the subject into a USA TODAY print insert and related digital coverage during Epilepsy Awareness Month. That reach...

Continue Reading
Niron's $1.8B Alabama Bet Carries Big Magnet Stakes

Updated Category News Views 54

A Huge Factory Claim Needs More Than Applause A magnet company just tossed a very large number onto Alabama's economic-development table. Niron Magnetics says it plans a $1.8 billion investment in the state that would create 700 jobs. That is not pocket change, not a ribbon-cutting trinket, and not the sort of announcement investors should breeze past between earnings...

Continue Reading

Top 5 Most Recently Viewed Articles

PAPZIMEOS Emerges as the Go-To Treatment for RRP Patients

Updated Category News Views 104

PAPZIMEOS: A Promising New Standard for RRP Therapy PAPZIMEOS (zopapogene imadenovec) has gained recognition as an innovative treatment for adults suffering from recurrent respiratory papillomatosis (RRP). This breakthrough comes following the publication of a consensus paper authored by 16 leading experts in the field. Sponsored by the Recurrent Respiratory...

Continue Reading
Ollie's Bargain Outlet Reports Encouraging Q2 Results

Updated Category News Views 159

Ollie's Bargain Outlet Achieves Strong Q2 Performance Ollie's Bargain Outlet Holdings, Inc. (NASDAQ: OLLI) has made headlines recently as its shares experience fluctuations in the market. The company revealed impressive second-quarter adjusted earnings per share of 99 cents, surpassing analyst expectations of 94 cents. The quarterly sales reached $679.556 million, marking...

Continue Reading
Fivecast Introduces Groundbreaking Discovery Solution for OSINT

Updated Category News Views 184

Fivecast Unveils Discovery Solution to Combat Global Threats In today's rapidly evolving landscape of global threats, Fivecast, a prominent provider of advanced open-source intelligence (OSINT) solutions, has rolled out an innovative Discovery solution designed to assist analysts and investigators in both government and corporate settings. By elevating the speed and...

Continue Reading
Zen Technologies USA Advances Military Training with AI Simulations

Updated Category News Views 224

Zen Technologies USA Showcases Cutting-Edge AI Simulations Zen Technologies USA is set to revolutionize military training capabilities with its next-generation AI-enabled live and virtual simulation solutions. By enabling high-fidelity training for ground and naval forces, these innovations aim to accelerate the readiness of military units while significantly reducing...

Continue Reading
Sectra and Siemens Healthineers Transform Radiology Workflows

Updated Category News Views 494

Revolutionizing Radiology with Innovative Integrations International medical imaging IT and cybersecurity company Sectra (STO: SECT B) and Siemens Healthineers AG have formed a pivotal collaboration aimed at enhancing diagnostic capabilities in the radiology field. This initiative seeks to improve patient care by enabling seamless access to advanced imaging technologies....

Continue Reading